Éric Solary
YOU?
Author Swipe
View article: Table S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
guide RNA for T7 knockdown of TET2 (related to Fig 1, Fig S1)
View article: Figure S7 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S7 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 6 but which were not included in the main figure
View article: Table S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
gRNAs for generation of MALAT1 knockout THP-1 cells (related to Fig S7)
View article: Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
qRT-PCR primer sequences (related to Fig 1, Fig S3, Fig S7)
View article: Figure S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 5 but which were not included in the main figure
View article: Figure S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 3 but which were not included in the main figure
View article: Table S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
qRT-PCR primers for confirming MALAT1 knockout across transcript. (Related to Fig S7)
View article: Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 4 but which was not included in the main figure
View article: AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosis
AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosis Open
Mastocytosis is a clonal disorder driven by KIT mutations, but resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge. Following the discovery of an AXL L197M mutation in a patient with congenital aggressive mastocytosis…
View article: Intercepter le cancer
Intercepter le cancer Open
View article: Pro-inflammatory role of granzyme K producing bystander CD8<sup>+</sup> T cells in acute myeloid leukemia
Pro-inflammatory role of granzyme K producing bystander CD8<sup>+</sup> T cells in acute myeloid leukemia Open
Acute myeloid leukemia (AML) is a heterogeneous group of blood malignancies with a 5-year survival rate below 30%, highlighting the urgent need for more effective therapeutic strategies. T cell-based immunotherapies have demonstrated remar…
View article: Protocol for quantification of circulating immature granulocytes in patients with a chronic myeloid malignancy using flow cytometry
Protocol for quantification of circulating immature granulocytes in patients with a chronic myeloid malignancy using flow cytometry Open
View article: Sugar free transforming growth factor β1 increases the fitness of myelodysplastic neoplasm / acute myeloid leukemia cells
Sugar free transforming growth factor β1 increases the fitness of myelodysplastic neoplasm / acute myeloid leukemia cells Open
Not available.
View article: Macrophage caspase-8 inhibition accelerates necrotic core expansion in atheroma plaque in mice
Macrophage caspase-8 inhibition accelerates necrotic core expansion in atheroma plaque in mice Open
Background and aims Cell death plays a central role in atheroma plaque progression and aggravation. This study investigates the role of caspase-8 in regulating macrophage cell death modalities, specifically apoptosis and necroptosis, withi…
View article: Granulocyte Derived Resistin Inhibits Monocyte Maturation and Induces Immune Suppression in CMML
Granulocyte Derived Resistin Inhibits Monocyte Maturation and Induces Immune Suppression in CMML Open
Chronic myelomonocytic leukaemia (CMML) is a haematological malignancy characterised by overlapping myeloid dysplasia and proliferation with persisting monocytosis. While monocytes are the cardinal malignant cell type in CMML, as a stem ce…
View article: Figure S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data showing Malat1 depletion has no effect on myelopoiesis or self-renewal
View article: Figure S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 1 but which were not included in the main figure
View article: Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis Open
View article: Table S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S1 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
gRNAs for generation of MALAT1 knockout THP-1 cells (related to Fig S7)
View article: Figure S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 3 but which were not included in the main figure
View article: Table S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Taqman assays for murine cytokine gene expression (related to Fig S6)
View article: Table S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
guide RNA for T7 knockdown of TET2 (related to Fig 1, Fig S1)
View article: Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S3 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
qRT-PCR primer sequences (related to Fig 1, Fig S3, Fig S7)
View article: Figure S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S6 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 5 but which were not included in the main figure
View article: Table S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
qRT-PCR primers for confirming MALAT1 knockout across transcript. (Related to Fig S7)
View article: Figure S7 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S7 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 6 but which were not included in the main figure
View article: Figure S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S2 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 2 but which were not included in the main figure
View article: Table S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Table S5 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
primer sequences for EGR1 Chromatin Immunoprecipitation (ChIP) (related to Fig S2)
View article: Data from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Data from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis. These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflam…
View article: Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis
Figure S4 from RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in <i>TET2</i>-Mutated Clonal Hematopoiesis Open
Contains data related to Figure 4 but which was not included in the main figure